KDR and neoplasm: Chiauranib inhibits tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment by targeting angiogenesis-related kinases [VEGF receptor 2 (VEGFR2), VEGFR1, VEGFR3, PDGF receptor alpha (PDGFRα), and c-KIT], mitosis-related kinase Aurora B and chronic inflammation related kinase CSF1R [54].